ING is the latest investor to back molecular diagnostics company Agendia BV. The bank has joined existing investors Gilde Healthcare Partners , Van Herk Biotech BV and Global Life Sciences Ventures on the company's fourth financing round, valued at EUR 25m.
Fourth core infrastructure secondaries fund is set to be twice the size of its predecessor
IK backed the France-based business in 2014 via its IK VII fund, which closed on €1.7bn in 2013
Move comes as funds invested in DC have exceeded £1bn, but exposure to private markets assets was already available to DB members
GP bought the fasteners and fixings manufacturer as part of a succession process for the company